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Abstract: Recent large trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) in the cardiovascular field did not demonstrate a beneficial effect in terms of 
reductions of clinical endpoints like total mortality, sudden cardiac arrest or other major 
adverse cardiac events. Pertinent guidelines do not uniformly recommend EPA + DHA for 
cardiac patients. In contrast, in epidemiologic findings, higher blood levels of EPA + DHA 
were consistently associated with a lower risk for the endpoints mentioned. Because of low 
biological and analytical variability, a standardized analytical procedure, a large database 
and for other reasons, blood levels of EPA + DHA are frequently assessed in erythrocytes, 
using the HS-Omega-3 Index® methodology. A low Omega-3 Index fulfills the current 
criteria for a novel cardiovascular risk factor. Neutral results of intervention trials can be 
explained by issues of bioavailability and trial design that surfaced after the trials were 
initiated. In the future, incorporating the Omega-3 Index into trial designs by recruiting 
participants with a low Omega-3 Index and treating them within a pre-specified target range 
(e.g., 8%–11%), will make more efficient trials possible and provide clearer answers to the 
questions asked than previously possible. 
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1. Introduction 
Fish, marine oils, and their concentrates all serve as sources of the two marine omega-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as do some products from algae.  
To demonstrate an effect of EPA + DHA on heart health, a number of randomized, controlled 
intervention studies with clinical endpoints like overall mortality or a combination of adverse cardiac 
events were conducted in populations with elevated cardiovascular risk. One early intervention study 
with oily fish, rich in EPA + DHA, and some early studies with fish oil or fish oil concentrate or even 
purified EPA at doses ranging between 0.9 and 1.8 g/day indeed demonstrated effects in terms of fewer 
sudden cardiac deaths, fatal or non-fatal myocardial infarctions, or a combination of adverse cardiac 
events [1–6]. More recent trials did not demonstrate such effects [7–12]. Recent meta-analyses found no 
significant benefits on total mortality, cardiovascular mortality, and other adverse cardiac or 
cardiovascular events [13–18]. This is in contrast to findings in epidemiologic studies, where intake of 
EPA + DHA had been found to correlate generally with an up to 50% lower incidence of adverse cardiac 
events [18,19], and in even sharper contrast to epidemiologic studies based on levels of EPA + DHA, 
demonstrating e.g., a 10-fold lower incidence of sudden cardiac death associated with high levels of the 
fatty acids, as compared to low levels [20,21]. This seemingly contradictory evidence has led the 
American Heart Association to recommend “omega-3 fatty acids from fish or fish oil capsules (1 g/day) 
for cardiovascular disease risk reduction” for secondary prevention, whereas the European Society for 
Cardiology recommends “Fish at least twice a week, one of which to be oily fish”, but no supplements 
for cardiovascular prevention [22,23]. The more recent guidelines on treating patients with stable 
ischemic heart disease or patients after a myocardial infarction, targeting similar patient populations, do 
not recommend EPA + DHA [24,25]. At least in Europe, cardiologists do not routinely use EPA + DHA 
to reduce cardiovascular risk. 
A similar picture emerges for atrial fibrillation: In epidemiologic studies, consumption of EPA + DHA 
or higher levels of EPA + DHA were associated with lower risk for developing atrial fibrillation, while 
intervention studies found no effect [26–28]. Pertinent guidelines do not mention EPA + DHA [29].  
A similar picture also emerges for severe ventricular rhythm disturbances [20,21,30,31]. 
Why is it that trial results are at odds with results from epidemiology? What needs to be done to better 
translate the epidemiologic findings into trial results? The current review will try to shed some light on 
this issue, with a special consideration of the Omega-3 Index. 
2. The Omega-3 Index as a Cardiovascular Risk Factor 
At least some nutritional surveys do not provide valid data [32]. This may explain, why the relation of 
EPA + DHA in the diet to clinical events has been found to be looser than the relation of levels of EPA + 
DHA measured in blood to clinical events (e.g., [20,33]). A detailed discussion of the pros and cons of 
the various fatty acid compartments in which levels of omega-3 fatty acids (whole blood, whole plasma, 
plasma phospholipids, and others) should be measured is outside the scope of this review and can be 
found elsewhere [34]. The following points argue for the use of erythrocytes: erythrocyte fatty acid 
composition has a low biological variability, erythrocyte fat consists almost exclusively of 
phospholipids, erythrocyte fatty acid composition reflects tissue fatty acid composition, pre-analytical 
stability, and other points [34–38]. In 2004, EPA + DHA in erythrocyte fatty acids were defined as the 
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Omega-3 Index and suggested as a risk factor for sudden cardiac death [39]. Integral to the definition 
was a specific and standardized analytical procedure, conforming the quality management routinely 
implemented in the field of clinical chemistry [39] In fatty acid analysis, methods have a large impact on 
results: when one sample was sent to five different laboratories offering determination of an Omega-3 
Index, results differed by a factor of 3.5 [34]. While results may be internally valid in one laboratory,  
a difference by a factor of 3.5 makes it impossible to compare results among laboratories. Therefore,  
the Omega-3 Index was renamed HS-Omega-3 Index®. In contrast, the laboratories adhering to the 
HS-Omega-3 Index methodology perform regular proficiency testing, as mandated in routine Clinical 
Chemistry labs [34]. So far, the HS-Omega-3 Index is the only analytical procedure used in several 
laboratories. A standardized analytical procedure is a prerequisite to generate the data base necessary to 
transport a laboratory parameter from research into clinical routine. Moreover, standardization of the 
analytical procedure is the first important criterion for establishing a new biomarker for cardiovascular 
risk set forth by the American Heart Association and the US Preventive Services Task Force [40,41]. 
As exemplified by Table 1, the HS-Omega-3 Index has been measured in many populations. Of note, 
a lower HS-Omega-3 Index was always associated with a poorer clinical condition (Table 1). 
Table 1. Mean HS-Omega-3 Index values in various populations, Mean (±standard 
deviation (SD)). Please note that in every population studied, a lower value was found to be 
associated with a worse condition than a higher value. References are given, if not, 
unpublished, n = number of individuals measured. 
Population HS-Omega-3 Index 
Western countries (high incidence of coronary heart disease)  
Germany  
Unselected Individuals (n = 5000) 7.15 (±2.19)% 
Patients with atherosclerosis [42], (n = 190) 5.94 (±1.41)% 
Patients with hyperlipidemia [43], (n = 47) 7.00 (±1.90)% 
Pregnant women, week 24 (n = 103) 7.66 (±1.83)% 
Patients with congestive heart failure (n = 895) 3.47 (±1.20)% 
Patients with major depression [44], (n = 90) 3.93 (±1.50)% 
Spain  
Individuals with high risk for, but without  
cardiovascular disease [45], (n = 198) (SD not reported) 
7.10% 
Norway  
Patients with myocardial infarction [46] (SD not reported)  
With ventricular fibrillation (n = 10) 4.88% 
Without ventricular fibrillation (n = 185)  6.08% 
Europe  
Unselected data from routine determinations, n = 10,000 6.96 (+2.15)% 
USA  
Healthy in Kansas City [47], (n = 163) 4.90 (±2.10)% 
Framingham-Offspring [48], (n = 3196) 5.60 (±1.70)% 
Patients with stable coronary heart disease [49],  
(n = 956) (SD not reported) 
4.60% 
Patients with major depression [50], (n = 118) 2.90 (±1.50)% 
Adolescents with major depression [51],  
(n = 150) (SD not reported) 
3.46% 
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Table 1. Cont. 
Patients with severe obstructive sleep apnea [52],  
(n = 52) (SD not reported) 
4.00% 
Saudi Arabia  
Individuals, most with diabetes (n = 69) 3.47 (±1.20) % 
Asian countries (low incidence of coronary heart disease)  
Korea  
Healthy controls [53], (n = 50) (SD not reported) 11.81% 
Healthy control [54], (n = 40) 10.55 (±0.48)% 
Patients with myocardial infarction [53],  
(n = 50), (SD not reported) 
9.57% 
Patients with hemorrhagic brain infarction [54], (n = 40) 8.55 (±0.41)% 
Patients with ischemic brain infarction [54], (n = 40) 8.19 (±0.64)% 
Hemodialysis-patients without calcification  
on plain chest radiograph [55], (n = 11) 
9.82 (±2.37)% 
Hemodialysis-patients with calcification  
on plain chest radiograph [55], (n = 20) 
9.23 (±2.34)% 
Peritoneal Dialysis Patients [56], (n = 14) 12.83 (±3.30)% 
Patients with a kidney transplant [57], (n = 49) 9.70 (±1.85)% 
Japan  
Unselected men (n = 262), (SD not reported) 9.58% 
All levels of fatty acids are determined by the balance of substance entering the body and those 
leaving the body. Neither a recent meal, even if rich in EPA + DHA, nor severe cardiac events altered 
the HS-Omega-3 Index [38,58–61]. However, while long-term intake of EPA + DHA, e.g., as assessed 
with food questionnaires, was the main predictor of the HS-Omega-3 Index, long-term intake explained 
only 12%–25% of its variability [46,62,63]. A hereditary component of 24% exists [64].  
A number of other factors correlated positively (+) or negatively (−), like age (+), body mass index (−), 
socioeconomic status (+), smoking (−), but no other conventional cardiac risk factors [47,64–71]. More 
factors determining the level of the HS-Omega-3 Index, especially regarding efflux remain to be 
defined. Therefore, it is impossible to predict the HS-Omega-3 Index in an individual, as it is impossible 
to predict the increase in the HS-Omega-3 Index in an individual in response to a given dose of EPA + 
DHA [42,46,62,63]. In Table 2, current evidence is presented on the relation of the HS-Omega-3 Index 
to cardiovascular events. 
This evidence is supported by measurements of EPA + DHA in other fatty acid compartments,  
as discussed in more detail elsewhere [72,73]. Within the framework of “Heart and Soul” and 
“Triumph”, it was investigated whether determination of the HS-Omega-3 Index added to the 
information obtained by assessing cardiovascular risk with a conventional scoring system, like the 
Framingham or GRACE scores for predicting fatal events. The HS-Omega-3 Index provided additional 
information, as demonstrated by larger areas under the curves in various c-statistics for fatal [74] and 
non-fatal events [53,75]. Taken together, the HS-Omega-3 Index predicts risk, appears largely 
independent of conventional risk factors, and adds to the information obtained by conventional risk 
scoring, thus fulfilling the second criterion for establishing a new biomarker for cardiovascular risk set 
forth by the American Heart Association and the US Preventive Services Task Force [40,41].
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Table 2. Summary of epidemiologic studies relating the Omega-3 Index to cardiovascular events. 
Acronym [reference] Design Disease n Years Criterion Comparison Result 
Total mortality        
Heart & Soul [49] cohort stable CAD 956 5.9 total mortality HS-Omega-3 Index HR 0.73; 95% CI, 0.56–0.94 
Triumph [74] cohort recent MI 1144 2 total mortality EPA in red cells tertiles 
EPA < 0.25% total mortality 26%, 
0.25 < EPA < 0.8% total mortality 
13%, EPA > 0.80% total  
mortality 7% 
Triumph [76] cohort recent MI 1424 1 total mortality  HS-Omega-3 Index < 4% vs. >4.0% HR 2.0; 95% CI 1.2–3.3 
Racs * [77] cohort recent ACS 460 2 total mortality HS-Omega-3 Index in quartiles not significant. 
Sudden cardiac death        
[20] case-control SCD 
82/108  
cases/controls
 SCD red cell EPA + DHA in quartiles OR 1.0–0.1 (95% CI 0.1–0.4) 
Phys Health [21] case-control SCD 
84/182  
cases/controls
 SCD whole blood EPA + DHA in quartiles
OR 1.0–0.1 (95% CI 0.02–0.48) 
across quartiles 
Cardiac morbidity        
[78] case-control ACS 
94/94  
cases/controls
 ACS whole blood EPA + DHA in quintiles
OR 1.0–0.2  
(95% CI not reported),  
OR 0.67 (95% CI 0.46 to 0.98) per, 
1 standard deviation increase  
EPA + DHA 
[79] case-control ACS 
768/768  
cases/controls
 ACS HS-Omega-3 Index in tertiles 
OR 1.0–0.31 (95% CI 0.14–0.67) 
across tertiles 
[53] case-control ACS 
50/50  
cases/controls
 ACS HS-Omega-3 Index in tertiles 
OR 1.0–0.08 (95% CI 0.02–0.38) 
across tertiles 
no acronym [80] case-control ACS 
24/68  
cases/controls
 STEMI HS-Omega-3 Index in tertiles 
OR 6.38 (95% CI  
1.02–39.85)–1.0 across tertiles 
Abbreviations: n: number of individuals studied; Coronary artery disease: CAD; HR: hazard ratio; MI: myocardial infarction; EPA: eicosapentaenoic acid; ACS: acute coronary syndrome; 
SCD: sudden cardiac death; DHA: docosahexaenoic acid; OR: odds ratio; STEMI: ST-elevation myocardial infarction. * No case estimate was reported in Racs. Therefore, by definition, it is 
unclear, whether the discriminatory power of the HS-Omega-3 Index was too small, or the study was too small to detect the discriminatory power. 
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Moreover, the HS-Omega-3 Index has made it possible to reclassify individuals from intermediate 
cardiovascular risk into the respective high risk and low risk strata [74,75], the third criterion for 
establishing a new biomarker for cardiovascular risk [40,41]. 
Increasing the HS-Omega-3 Index by increased intake of EPA + DHA in randomized controlled trials 
improved a number of surrogate parameters for cardiovascular risk: heart rate was reduced, heart rate 
variability was increased, blood pressure was reduced, platelet reactivity was reduced, triglycerides were 
reduced, large buoyant low-density lipoprotein (LDL)-particles were increased and small dense 
LDL-particles were reduced, large buoyant high-density lipoproteins (HDL)2 were increased, very 
low-density lipoprotein (VLDL1) + 2 was reduced, pro-inflammatory cytokines (e.g., tumor necrosis 
factor alpha, interleukin-1β, interleukins-6,8,10 and monocyte chemoattractant protein-1) were reduced, 
anti-inflammatory oxylipins were increased [43,81–94]. Importantly, in a two-year randomized 
double-blind angiographic intervention trial, increased erythrocyte EPA + DHA reduced progression 
and increased regression of coronary lesions, an intermediate parameter [95]. Taken together, increasing 
the HS-Omega-3 Index improved surrogate and intermediate parameters for cardiovascular events.  
A large intervention trial with clinical endpoints based on the HS-Omega-3 Index remains to be 
conducted. Therefore, the fourth criterion, proof of therapeutic consequence of determining the  
HS-Omega-3 Index, is only partially fulfilled [40,41]. 
3. Discussion of Neutral Results of Large Intervention Trials 
Why is it that a low HS-Omega-3 Index can be a cardiovascular risk factor, and yet the results of the 
large trials testing EPA + DHA on clinical endpoints were neutral? 
3.1. Bioavailability Issues 
According to personal information from the respective first authors, participants of recent large 
intervention trials were advised to take their supplements, frequently an encapsulated EPA + DHA 
ethyl-ester with breakfast—in many countries a low-fat meal [7–11]. As discussed in more detail in a 
recent review, bioavailability of EPA + DHA depends on the chemical form in which they are bound 
(phospholipids > recombined triglycerides > triglycerides > free fatty acids > ethyl-esters) [96,97], on 
matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form 
(i.e., microencapsulation, emulsification). The chemical binding form impacts on bioavailability roughly 
with a factor of two, whereas matrix effects can impact bioavailability up to a factor of 13, and the 
galenic form up to a factor of 21 [96–99]. When the large trials mentioned here were designed, the 
bioavailability issues just mentioned were unknown. Thus, involuntarily, the combination used in many 
of the large trials—An unemulsified ethyl-ester or triglyceride with a low fat meal—guaranteed a very 
low bioavailability of EPA + DHA. 
3.2. Issues in Trial Design 
In all large intervention trials conducted so far, study participants were recruited based on clinical 
conditions, but irrespective of their baseline omega-3 fatty acid status [1–12]. In all populations studied 
so far, the HS-Omega-3 Index had a statistically normal distribution (Table 1). Thus, the proportion of 
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the study population with high levels was not prone to the effects of EPA + DHA, if any. In order to 
recruit a study population, in which an effect of EPA + DHA can be demonstrated, recruiting study 
participants with a low HS-Omega-3 Index is a logical choice. 
In all large intervention trials conducted so far, study participants were exposed to a trial-specific, but 
fixed dose of EPA + DHA or placebo [1–12]. The inter-individual variability in response to a fixed dose 
of EPA + DHA has been found to be large, i.e., vary up to a factor of 13 [42,61]. This fact alone suggests 
individualizing the dose given in a trial, in order to reach a predefined target range of the  
HS-Omega-3 Index, e.g., 8%–11%. The statistically normal distribution of the baseline HS-Omega-3 
Index further complicates this problem: A large overlap of omega-3 levels in the EPA + DHA group and 
placebo or control group can be expected, and has been seen in at least one large trial (Mühlhäusler, B., 
personal communication) [100]. With levels of omega-3 fatty acids not differing between intervention 
and placebo or control groups, a difference in study outcome cannot be expected, even if the condition 
studied would be susceptible to treatment with EPA + DHA. It is worth noting that when a neutral 
intervention trial was analyzed in a cross-sectional way, EPA + DHA levels directly related to study 
outcome and less to treatment allocation [101]. 
Conversely, if a trial reports a positive result, it is likely to have been conducted in a study population 
with low baseline levels of EPA and DHA, like congestive heart failure: a positive result of a large trial 
was reported [6], and we found a low mean HS-Omega-3 Index in patients with congestive heart  
failure (unpublished data, Table 1). A similar case can be made for major depression (Table 1,  
references [44,50,51,84]). 
In the future, recruiting study participants with a low baseline HS-Omega-3 Index and treating them 
within a predefined target range will allow clearer trial results to be a distinct possibility. Dose 
adjustments will need to be performed in the placebo group. Since a larger treatment effect can be 
assumed in the study size estimation, it can be expected that study sizes will be smaller and thus studies 
less expensive. Clearly, these thoughts are not restricted to trials with patients with cardiovascular risk, 
atrial fibrillation or ventricular arrhythmia, but can be extended to all areas of omega-3 fatty  
acid research. This will facilitate scientific progress and lead to a faster recognition of the effects of  
EPA + DHA. 
4. Conclusions 
In an inconsistent manner, EPA and DHA are either recommended or not included in guidelines of 
cardiac scientific societies. The use of EPA and DHA is not supported by results of recent intervention 
trials or their meta-analyses. However, epidemiologic data based on assessments of diet and, even more 
so, data based on levels of EPA + DHA measured in humans, clearly demonstrate that EPA + DHA are 
associated with a low risk for total mortality, sudden cardiac arrest, and fatal and non-fatal myocardial 
infarctions. For a number of reasons, like a standardized analytical procedure and a large data base, 
levels of EPA + DHA are best assessed with the HS-Omega-3 Index. According to current criteria of the 
American Heart Association and others, the HS-Omega-3 Index is a novel cardiovascular risk factor. 
Moreover, the HS-Omega-3 Index has led to a fresh look at the field of omega-3 fatty acids and has made 
it possible to identify issues of bioavailability and study design, explaining at least in part the neutral 
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results of previous intervention trials. In the future, more efficient intervention studies can be conducted 
based on the HS-Omega-3 Index, thus providing a clearer picture of the effects of EPA + DHA. 
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